loading
Schlusskurs vom Vortag:
$32.69
Offen:
$32.69
24-Stunden-Volumen:
316.34K
Relative Volume:
0.22
Marktkapitalisierung:
$3.72B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-11.28
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+5.74%
1M Leistung:
+9.54%
6M Leistung:
-22.12%
1J Leistung:
+27.48%
1-Tages-Spanne:
Value
$32.54
$33.62
1-Wochen-Bereich:
Value
$30.66
$33.62
52-Wochen-Spanne:
Value
$21.51
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Firmenname
Avidity Biosciences Inc
Name
Telefon
858-401-7900
Name
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
391
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
RNA's Discussions on Twitter

Vergleichen Sie RNA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNA
Avidity Biosciences Inc
32.59 3.72B 10.12M -280.49M -188.51M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.27 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
609.76 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
651.64 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.74 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.30 26.40B 3.81B -644.79M -669.77M -6.24

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet Citigroup Buy
2025-03-12 Eingeleitet BMO Capital Markets Outperform
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-12-20 Eingeleitet H.C. Wainwright Buy
2024-11-26 Eingeleitet RBC Capital Mkts Outperform
2024-09-24 Eingeleitet Goldman Buy
2024-08-28 Eingeleitet Barclays Overweight
2024-05-03 Eingeleitet BofA Securities Buy
2024-03-14 Eingeleitet Cantor Fitzgerald Overweight
2023-05-22 Hochstufung Evercore ISI In-line → Outperform
2023-03-31 Herabstufung Evercore ISI Outperform → In-line
2022-07-20 Eingeleitet Chardan Capital Markets Buy
2022-07-12 Eingeleitet Raymond James Strong Buy
2021-09-07 Eingeleitet Evercore ISI Outperform
2021-06-17 Eingeleitet Needham Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-07-07 Eingeleitet Cowen Outperform
2020-07-07 Eingeleitet Credit Suisse Outperform
2020-07-07 Eingeleitet SVB Leerink Outperform
2020-07-07 Eingeleitet Wells Fargo Overweight
Alle ansehen

Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten

pulisher
Apr 30, 2025

Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada

Apr 30, 2025
pulisher
Apr 29, 2025

Avidity Biosciences appoints Deloitte as new auditor - Investing.com

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 22, 2025

Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus

Apr 22, 2025
pulisher
Apr 21, 2025

Avidity Biosciences Expands Team with 33 New Hires, Grants $10M+ in Equity Incentives - Stock Titan

Apr 21, 2025
pulisher
Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025
pulisher
Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025
pulisher
Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025
pulisher
Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025
pulisher
Apr 02, 2025

When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 02, 2025

Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com

Apr 02, 2025
pulisher
Apr 01, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider

Apr 01, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times

Mar 31, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Mar 29, 2025
pulisher
Mar 26, 2025

The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 22, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise

Mar 22, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025

Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Avidity Biosciences Inc-Aktie (RNA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Gallagher Kathleen P.
Chief Program Officer
Apr 01 '25
Option Exercise
14.81
5,875
87,004
56,100
Gallagher Kathleen P.
Chief Program Officer
Apr 01 '25
Sale
27.83
5,875
163,486
50,554
Hughes Steven George
Chief Medical Officer
Mar 20 '25
Sale
31.06
9,578
297,491
72,850
Boyce Sarah
President and CEO
Mar 20 '25
Sale
31.06
31,540
979,563
305,871
Flanagan W. Michael
Chief Scientific Officer
Mar 20 '25
Sale
31.06
11,780
365,868
80,195
MacLean Michael F
Chief Financial Officer
Mar 20 '25
Sale
31.06
7,935
246,425
96,720
McCarthy Teresa
Chief Human Resources Officer
Mar 20 '25
Sale
31.06
7,778
241,583
97,130
Flanagan W. Michael
Chief Scientific Officer
Mar 11 '25
Option Exercise
14.22
20,000
284,400
111,975
Flanagan W. Michael
Chief Scientific Officer
Mar 11 '25
Sale
30.13
20,000
602,614
91,975
$72.51
price down icon 0.01%
$21.58
price up icon 2.96%
$32.56
price up icon 0.06%
$29.24
price up icon 18.78%
$105.61
price up icon 3.06%
biotechnology ONC
$256.40
price up icon 0.63%
Kapitalisierung:     |  Volumen (24h):